Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06567197
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-25
Brief Title:
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation MS-ACT A Long-term Prospective Observational Study in the Netherlands
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MS-ACT
Brief Summary:
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation aHSCT in people with highly active relapsing-remitting multiple sclerosis The study will evaluate the following items
1 Disease activity
2 Safety and tolerability of aHSCT
3 Changes in the immune system
Participants will be subjected to frequent visits for five years after treatment with aHSCT During these visits clinical testing evaluation by questionnaires MRI scans and blood sampling will be performed
1 Disease activity
2 Safety and tolerability of aHSCT
3 Changes in the immune system
Participants will be subjected to frequent visits for five years after treatment with aHSCT During these visits clinical testing evaluation by questionnaires MRI scans and blood sampling will be performed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None